The next challenge for Gene Therapy

Two deaths have been reported in a trial to extend the indication for gene therapy for Duchenne muscle dystrophy, suspected to be due to hepatotoxic side effects of the AAV vector. Dose reduction and improvements such as organ-directedness have become essential.
https://miyata-bio.net/column/0000453/